

Xi Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10016895/publications.pdf>

Version: 2024-02-01

27
papers

2,635
citations

759233

12
h-index

677142

22
g-index

30
all docs

30
docs citations

30
times ranked

4538
citing authors

#	ARTICLE	IF	CITATIONS
1	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. <i>Cell</i> , 2018, 172, 90-105.e23.	28.9	794
2	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. <i>Cell Stem Cell</i> , 2018, 22, 191-205.e9.	11.1	749
3	<i>TET1</i> plays an essential oncogenic role in <i>MLL</i> -rearranged leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11994-11999.	7.1	185
4	Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia. <i>Cancer Cell</i> , 2012, 22, 524-535.	16.8	154
5	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012, 119, 2314-2324.	1.4	145
6	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. <i>Nature Communications</i> , 2012, 3, 688.	12.8	138
7	miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. <i>Nature Communications</i> , 2016, 7, 11452.	12.8	113
8	miR-495 is a tumor-suppressor microRNA down-regulated in <i>MLL</i> -rearranged leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19397-19402.	7.1	109
9	EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity. <i>Nature Communications</i> , 2019, 10, 3892.	12.8	95
10	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. <i>Cancer Research</i> , 2016, 76, 4470-4480.	0.9	48
11	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. <i>Nature Communications</i> , 2017, 8, 2099.	12.8	45
12	ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. <i>Scientific Reports</i> , 2017, 7, 1853.	3.3	26
13	miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. <i>International Journal of Biological Sciences</i> , 2020, 16, 2853-2867.	6.4	11
14	Anti-Tumor Effects of BDH1 in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 694594.	2.8	6
15	Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. <i>Cell Reports</i> , 2022, 38, 110253.	6.4	6
16	The N6-Adenine Methyltransferase METTL14 Plays an Oncogenic Role in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1536-1536.	1.4	1
17	Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia. <i>Blood</i> , 2012, 120, 3499-3499.	1.4	1
18	Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling. <i>Blood</i> , 2015, 126, 3667-3667.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia. Blood, 2017, 130, 857-857.	1.4	1
20	Protocol to establish a stable MLL-AF9_AML mouse model. STAR Protocols, 2022, 3, 101559.	1.2	1
21	Repression of Mir-495, a Microrna Associated with Favorable Outcome of Acute Myeloid Leukemia Patients, Is Required for the MLL-Associated Leukemogenesis,. Blood, 2011, 118, 3462-3462.	1.4	0
22	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. Blood, 2011, 118, 236-236.	1.4	0
23	The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia. Blood, 2012, 120, 3522-3522.	1.4	0
24	MLL-Associated Leukemias Drive Expression of MiR-9, Required for Tumorigenesis. Blood, 2012, 120, 525-525.	1.4	0
25	MLL-Rearranged Acute Myeloid Leukemias Drive Expression Of Mir-9, a Critical Oncogene In Leukemogenesis. Blood, 2013, 122, 3740-3740.	1.4	0
26	Alox5 Functions As Both Tumor Suppressor and Drug Sensitizer in AML. Blood, 2016, 128, 2851-2851.	1.4	0
27	N6-Methyladenosine Modification Regulates Cell Metabolism in Acute Myeloid Leukemia. Blood, 2018, 132, 880-880.	1.4	0